PLOT # 183 (7th FLOOR), BLOCK # B, AHMED AKBER SOBHAN ROAD, BASHUNDHARA R/A, Dhaka-1229.

PRICE SENSITIVE INFORMATION

This is for kind information that the Board of Directors in its meeting held **on Wednesday 27th January, 2021 at 4:00 p.m.** at the corporate office of the company has approved the Un-Audited Financial Statements for the Second Quarter (Q2) period ended on 31th December, 2020 as per Regulation-16 of Dhaka Stock Exchange (Listing) Regulation, 2015.

The key financial highlights for the Second Quarter ended 31th December, 2020 are appended below:

Particulars	As at 31.12.2020	As at 30.06.2020
Net Asset Value (NAV) Per Share	Tk. 13.77	Tk. 13.61

Particulars	July to December 2020	July to December 2019	October to December 2020	October to December 2019
Earnings Per Share (EPS)	Tk. 0.66	Tk. 0.83	Tk. 0.33	Tk.0.44
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.68	Tk. 0.82	-	-

This is for your kind information and record.

By order of the Board of Directors

-sd-

(Mohi Uddin QCS) Company Secretary

The details of the published Second Quarter (Q2) Financial Statements are available in the website of the company: www.indo-banglapharma.com.